Ali Erdinc Ciftciler

Bio: Ali Erdinc Ciftciler is an academic researcher. The author has contributed to research in topics: Bone marrow & Microbiome. The author has an hindex of 2, co-authored 5 publications receiving 5 citations.

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

Abstract: Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects.

Local bone marrow renin-angiotensin system and covid-19/ Lokal kemik iliği renin anjiotensin sistem ve covid-19

Abstract: For the first time on December 31, 2019, 27 cases of pneumonia of unknown etiology were detected in Wuhan City, Hubei province, China. The factor that caused this clinic was called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In the following days, WHO officially named the disease caused by the new coronavirus as Coronavirus Disease 2019 (COVID-19). Patients infected with SARS-CoV-2 mostly applied to health centers with symptoms of dry cough, shortness of breath and fever. some patients have developed death-causing complications such as organ failure, septic shock, pulmonary edema, severe pneumonia, and Acute Respiratory Distress Syndrome (ARDS). SARS-CoV-2 infects patients by binding human Angiotensin Converting Enzyme 2 (ACE 2), causing to severe pneumonia and high mortality. Circulating RAS and local paracrin-autocrin-intracrin tissue-based RAS participate in numerous pathobiological events. Pro-inflammatory, pro-fibrotic, and pro-thrombotic consequences associated with local RAS activation have been detected at cellular and molecular level. Regenerative progenitor cell therapy in response to RAS-modulating pharmacotherapy in context of endothelial cell damage and regeneration emerged as an auxiliary therapy to improve regeneration of the vascular endothelium. The aim of this article is to evaluate the relationship between circulating and local angiotensin systems and COVID-19.

Follow-up of Patients with Atypical Lymphoproliferation in Bone Marrow or Lymph Node Biopsy

Abstract: Objective: Patients presenting with various complaints to the hematology polyclinic may initially be diagnosed with an atypical lymphoproliferation in bone marrow or lymph node biopsy The aim of this study was to determine whether a hematological disease, immunodeficiency syndrome, or other diseases were diagnosed during follow-up of patients with an initial diagnosis of atypical lymphoproliferation in bone marrow or in lymph node biopsy Materials and Methods: Adult (≥18 years) patients who were admitted to the Hacettepe University Hospital, for various symptoms between 2002 and 2018 were searched for in our hematology department electronical database Results: A total of 52 patients were found with atypical lymphoproliferation in lymph node or bone marrow biopsy The patients had been followed for a median of 92 months (003-862) Hematological neoplasia developed in 32 (616%) of the 52 patients and primary immunodeficiency was detected in 6 (115%) of the 52 patients Twenty-six patients (50%) were diagnosed Non-Hodgkin lymphoma during follow up, 1 patient (1%) was diagnosed chronic lymphocytic leukemia, 5 patients (96%) were diagnosed Hodgkin lymphoma and 6 patients (115%) were diagnosed primary immunodeficiency Median time was 23 months (02-25 months) between atypical lymphoproliferation report in bone marrow or lymph node biopsy and the diagnosis of patients Conclusion: In conclusion, patients who have atypical lymphoproliferation in the lymph node or bone marrow biopsy should be followed up in the hematology outpatient clinic Because, during follow-up, diseases such as hematological neoplasia or immunodeficiency can be diagnosed in patients with atypical lymphoproliferation

Hematological aspects of the COVID-19 syndrome.

Abstract: OBJECTIVE Viral infections could complicate hematopoiesis and, in some cases, they may worsen the clinical prognosis of blood disorders. SARS-CoV-2 and COVID-19, as a viral disease, can have serious impact on the disease course of hematological neoplastic diseases and can cause hematological complications. The aim of this paper is to review the hematologic aspects of COVID-19 syndrome and the potential management options for SARS-CoV-2 including the convalescent plasma, hemostatic agents and proper anticoagulant treatment. MATERIALS AND METHODS Up to February 2022, literature searches were performed using the internet search engines MEDLINE and EMBASE: (i) COVID-19; (ii) Hematology. PRISMA flow diagram described the COVID-19 and hematology search. RESULTS According to our COVID-19 and hematology research on research databases, we included 82 studies in the current paper. The issues of the impact of the COVID-19 pandemic on hematological diseases, the role of t-lymphocytes in donor lymphocyte infusion and viruses, hemato-immunologic research in COVID-19, local bone marrow renin-angiotensin system and viral infections, clinical management of COVID-19 infection via hemostatic agents, immune plasma treatment of COVID-19, anticoagulant treatment of COVID-19 associated thrombosis are comprehensively described in this paper. CONCLUSIONS The final episode of this pandemic will include the "chimerism-mediated immunotherapy" that will eventually lead to end of the COVID-19 process. The recent Omicron variant seems to have unique evasion effects on the interferon gene expression which will boost the chimerism-mediated immunotherapy without high mortality rates.

Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA

Abstract: Multiple myeloma has a long course, with no obvious symptoms in the early stages. However, advanced stages are characterized by injury to the bone system and represent a severe threat to human health. The results of the present work indicate that the hypermethylation of miR-23 promoter mediates the aberrant expression of uPA/PLAU (urokinase plasminogen activator, uPA) in multiple myeloma cells. miR-23, a microRNA that potentially targets uPA’s 3’UTR, was predicted by the online tool miRDB. The endogenous expressions of uPA and miR-23 are related to disease severity in human patients, and the expression of miR-23 is negatively related to uPA expression. The hypermethylation of the promoter region of miR-23 is a promising mechanism to explain the low level of miR-23 or aberrant uPA expression associated with disease severity. Overexpression of miR-23 inhibited the expression of uPA by targeting the 3’UTR of uPA, not only in MM cell lines, but also in patient-derived cell lines. Overexpression of miR-23 also inhibited in vitro and in vivo invasion of MM cells in a nude mouse model. The results therefore extend our knowledge about uPA in MM and may assist in the development of more effective therapeutic strategies for MM treatment.

Comparison of hemostatic efficacy of topical Ankaferd Blood Stopper on heparinized and nonheparinized rats in bleeding related to liver injury.

Abstract: Purpose: In this study, hemostatic efficacy of Ankaferd Blood Stopper (ABS), a new generation hemostatic agent, was compared in the presence of heparin effect Methods: Forty-eight Wistar albino rats were divided into two main groups as heparinized and nonheparinized, and these two main groupswere divided into six subgroups as control, Surgicel and ABS (n = 8) Grade 2 liver injury was performed on rats as standard All groups were compared in terms of weight, laceration surface area, prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR), bleeding time, bleeding amount, hemoglobin (Hb) levels, macroscopic and microscopic reactions to the agent used Results: Whereas there was no statistically significant difference between weight, laceration surface area, PT, INR and preoperative Hb values in the heparinized and nonheparinized groups, postoperative Hb, bleeding time, bleeding amount and aPTT values were statistically different (p 005), it was found that the Surgicel group had statistical significantly higher reaction scores (p < 005) than the other groups in terms of other parameters Conclusions: Ankaferd Blood Stopper can be safely and effectively used in surgical practice and in patients with additional diseases requiring heparinization, since it causes minimal reaction in the liver and decreases the amount of bleeding especially in the heparinized group